These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15747430)

  • 1. Pill burden reduced for saquinavir.
    AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747430
    [No Abstract]   [Full Text] [Related]  

  • 2. Searching for the right dose of ritonavir-saquinavir.
    TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
    [No Abstract]   [Full Text] [Related]  

  • 3. Boosted saquinavir approved.
    AIDS Patient Care STDS; 2004 Mar; 18(3):183. PubMed ID: 15112642
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):41. PubMed ID: 11012293
    [No Abstract]   [Full Text] [Related]  

  • 5. [New formulation--fewer tablets--optimal effect].
    Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
    [No Abstract]   [Full Text] [Related]  

  • 6. Combo approved for HIV treatment.
    Nurse Pract; 2004 Mar; 29(3):40. PubMed ID: 15052701
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination suppresses HIV RNA within the central nervous system.
    AIDS Patient Care STDS; 1998 Jan; 12(1):65. PubMed ID: 11361893
    [No Abstract]   [Full Text] [Related]  

  • 8. Saquinavir once daily.
    TreatmentUpdate; 2002; 14(4):4. PubMed ID: 12064314
    [No Abstract]   [Full Text] [Related]  

  • 9. From grapefruit juice to ritonavir.
    TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
    [No Abstract]   [Full Text] [Related]  

  • 10. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
    van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
    Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saquinavir/Ritonavir: its evolution and current treatment role.
    O'Brien WA
    AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saquinavir switch study stopped.
    Treat Rev; 1997 Apr; (No 24):6. PubMed ID: 11364285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New gel formulation for saquinavir.
    AIDS Patient Care STDS; 1997 Oct; 11(5):373-4. PubMed ID: 11361823
    [No Abstract]   [Full Text] [Related]  

  • 18. Twice daily saquinavir.
    AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356812
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
    Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
    Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.